SALL4 mediates teratogenicity as a thalidomide-dependent cereblon substrate-Reference-Cited by-同舟云学术

SALL4 mediates teratogenicity as a thalidomide-dependent cereblon substrate

Published:2018-09-06 Issue:10 Volume:14 Page:981-987
ISSN:1552-4450
Container-title:Nature Chemical Biology
language:en
Short-container-title:Nat Chem Biol

Author:

Matyskiela Mary E.,Couto Suzana,Zheng Xinde,Lu Gang,Hui Julia,Stamp Katie,Drew Clifton,Ren Yan,Wang Maria,Carpenter Aaron,Lee Chung-Wein,Clayton Thomas,Fang Wei,Lu Chin-Chun,Riley Mariko,Abdubek Polat,Blease Kate,Hartke James,Kumar Gondi,Vessey Rupert,Rolfe Mark,Hamann Lawrence G.,Chamberlain Philip P.

Publisher

Springer Science and Business Media LLC

Subject

Cell Biology,Molecular Biology

Link

http://www.nature.com/articles/s41589-018-0129-x.pdf

Reference48 articles.

1. Lenz, W. A short history of thalidomide embryopathy. Teratology 38, 203–215 (1988).

2. Vargesson, N. Thalidomide-induced teratogenesis: history and mechanisms. Birth Defects Res. C Embryo Today 105, 140–156 (2015).

3. Lenz, W. P., Pfeiffer, R. A., Kosenow, W. & Hayman, D. J. Thalidomide and congenital abnormalities. Lancet 279, 45–46 (1962).

4. Mcbride, W. G. Thalidomide and congenital abnormalities. Lancet 278, 1358 (1961).

5. Kim, J. H. & Scialli, A. R. Thalidomide: the tragedy of birth defects and the effective treatment of disease. Toxicol. Sci. 122, 1–6 (2011).

Cited by 229 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inducing or enhancing protein-protein interaction to develop drugs: Molecular glues with various biological activity;European Journal of Medicinal Chemistry;2024-11

2. Novel potent molecular glue degraders against broad range of hematological cancer cell lines via multiple neosubstrates degradation;Journal of Hematology & Oncology;2024-09-02

3. Revisiting the antiangiogenic mechanisms of fluorinated thalidomide derivatives;Bioorganic & Medicinal Chemistry Letters;2024-09

4. Discovery of KT-474─a Potent, Selective, and Orally Bioavailable IRAK4 Degrader for the Treatment of Autoimmune Diseases;Journal of Medicinal Chemistry;2024-08-16

5. Immunomodulatory drugs: a promising clinical ally for cancer immunotherapy;Trends in Molecular Medicine;2024-08